Clinical Trials Arena on MSN1d
IGC Pharma posts promising interim data for Alzheimer’s therapy
The results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.
Doctors didn't warn women of 'risky sex' drug urges
Prevalence rates of what GSK calls "deviant" sexual behaviours caused by the drugs are unknown and tend to be under-reported ...
IGC Pharma announces interim data from Phase 2 trial of IGC-AD1
IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for ...
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer’s - POTOMAC, MD / ACCESS Newswire / March ...